Biomarin Pharmaceutical Inc Cash Flow-to-Debt Ratio
Biomarin Pharmaceutical Inc cash flow-to-debt ratio. Biomarin Pharmaceutical Inc (BMRN) has a Cash Flow-to-Debt Ratio of 0.03x as of June 2026, meaning its operating cash flow of $168.11 Million could theoretically repay 0% of its total liabilities ($5.40 Billion) in one year. Check Biomarin Pharmaceutical Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Biomarin Pharmaceutical Inc (1998–2025)
Cash flow-to-debt ratio of Biomarin Pharmaceutical Inc from 1998 to 2025. Historical debt coverage capacity for Biomarin Pharmaceutical Inc across 28 annual periods. Check BMRN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Biomarin Pharmaceutical Inc Cash Flow-to-Debt Ratio by Year (1998–2025)
Biomarin Pharmaceutical Inc cash flow-to-debt ratio by year from 1998 to 2025. Year-by-year debt coverage analysis for Biomarin Pharmaceutical Inc. For the full cash flow conversion analysis, see Biomarin Pharmaceutical Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.55x | $827.99 Million | $1.51 Billion | ▲ +27.7% |
| 2024 | 0.43x | $572.84 Million | $1.33 Billion | ▲ +410.8% |
| 2023 | 0.08x | $159.26 Million | $1.89 Billion | ▼ -15.1% |
| 2022 | 0.10x | $175.90 Million | $1.77 Billion | ▼ -43.5% |
| 2021 | 0.18x | $304.54 Million | $1.73 Billion | ▲ +258.7% |
| 2020 | 0.05x | $85.36 Million | $1.74 Billion | ▲ +59.2% |
| 2019 | 0.03x | $48.26 Million | $1.57 Billion | ▲ +122.3% |
| 2018 | 0.01x | $20.21 Million | $1.46 Billion | ▲ +388.5% |
| 2017 | 0.00x | $-8.76 Million | $1.82 Billion | ▲ +97.4% |
| 2016 | -0.18x | $-227.84 Million | $1.26 Billion | ▼ -8.6% |
| 2015 | -0.17x | $-221.69 Million | $1.33 Billion | ▼ -118.4% |
| 2014 | -0.08x | $-73.54 Million | $962.56 Million | ▼ -15.7% |
| 2013 | -0.07x | $-59.63 Million | $903.02 Million | ▼ -307.2% |
| 2012 | 0.03x | $17.61 Million | $552.58 Million | ▼ -9.5% |
| 2011 | 0.04x | $18.75 Million | $532.66 Million | ▲ +2.4% |
| 2010 | 0.03x | $18.75 Million | $545.37 Million | ▼ -76.7% |
| 2009 | 0.15x | $87.73 Million | $594.98 Million | ▲ +1112.5% |
| 2008 | -0.01x | $-9.18 Million | $630.02 Million | ▲ +73.5% |
| 2007 | -0.05x | $-34.49 Million | $627.55 Million | ▲ +62.1% |
| 2006 | -0.14x | $-50.09 Million | $345.63 Million | ▲ +36.9% |
| 2005 | -0.23x | $-62.68 Million | $272.76 Million | ▼ -6.2% |
| 2004 | -0.22x | $-65.14 Million | $300.94 Million | ▲ +59.9% |
| 2003 | -0.54x | $-74.80 Million | $138.49 Million | ▲ +87.8% |
| 2002 | -4.44x | $-53.59 Million | $12.07 Million | ▼ -136.0% |
| 2001 | -1.88x | $-23.07 Million | $12.26 Million | ▼ -1.2% |
| 2000 | -1.86x | $-12.90 Million | $6.94 Million | ▲ +25.7% |
| 1999 | -2.50x | $-12.94 Million | $5.17 Million | ▲ +34.8% |
| 1998 | -3.84x | $-8.10 Million | $2.11 Million | — |